{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:22:32Z","timestamp":1789849352213,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3107,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1093\/annonc\/mdq629","type":"journal-article","created":{"date-parts":[[2011,2,12]],"date-time":"2011-02-12T03:09:53Z","timestamp":1297480193000},"page":"1280-1287","source":"Crossref","is-referenced-by-count":99,"title":["Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation"],"prefix":"10.1016","volume":"22","author":[{"given":"E.P.","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.B.Y.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.M.","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.Y.","family":"Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq629_bb0010","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1349-7006.2008.00836.x","article-title":"Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions","volume":"99","author":"Ma","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1093\/annonc\/mdq629_bb0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/cncr.20358","article-title":"Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group","volume":"101","author":"Hui","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq629_bb0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/cncr.20768","article-title":"Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma","volume":"103","author":"Ma","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq629_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/030089160208800405","article-title":"Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma","volume":"88","author":"Airoldi","year":"2002","journal-title":"Tumori"},{"key":"10.1093\/annonc\/mdq629_bb0030","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1368-8375(02)00120-3","article-title":"A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy","volume":"39","author":"Chua","year":"2003","journal-title":"Oral Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0035","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1200\/JCO.2005.02.147","article-title":"Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0040","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1046\/j.1523-1755.1999.00610.x","article-title":"Role of vascular endothelial growth factor in the regulation of angiogenesis","volume":"56","author":"Ferrara","year":"1999","journal-title":"Kidney Int"},{"key":"10.1093\/annonc\/mdq629_bb0045","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00005537-199905000-00024","article-title":"Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma","volume":"109","author":"Wakisaka","year":"1999","journal-title":"Laryngoscope"},{"key":"10.1093\/annonc\/mdq629_bb0050","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1097\/00005537-200012000-00017","article-title":"The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma","volume":"110","author":"Guang-Wu","year":"2000","journal-title":"Laryngoscope"},{"key":"10.1093\/annonc\/mdq629_bb0055","first-page":"2595","article-title":"Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival","volume":"8","author":"Hui","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq629_bb0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/BF03032375","article-title":"Morphometric study of tumor angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients","volume":"6","author":"Rubio","year":"2000","journal-title":"Pathol Oncol Res"},{"key":"10.1093\/annonc\/mdq629_bb0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<255::AID-CNCR2>3.0.CO;2-N","article-title":"Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma","volume":"88","author":"Qian","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq629_bb0070","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1073\/pnas.121016998","article-title":"Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells","volume":"98","author":"Murono","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdq629_bb0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1078\/0344-0338-00193","article-title":"Expression of p53 protein and tumor angiogenesis as prognostic factors in nasopharyngeal carcinoma patients","volume":"198","author":"Rubio","year":"2002","journal-title":"Pathol Res Pract"},{"key":"10.1093\/annonc\/mdq629_bb0080","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hed.10307","article-title":"Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma\u2014a prospective study","volume":"25","author":"Ma","year":"2003","journal-title":"Head Neck"},{"key":"10.1093\/annonc\/mdq629_bb0085","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ijrobp.2004.07.694","article-title":"Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505","volume":"61","author":"Foote","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdq629_bb0090","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1017\/S0022215100141878","article-title":"Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470)","volume":"112","author":"Qian","year":"1998","journal-title":"J Laryngol Otol"},{"key":"10.1093\/annonc\/mdq629_bb0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000011998","article-title":"Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC\/HK1","volume":"57","author":"Qian","year":"1999","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdq629_bb0100","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq629_bb0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10456-004-3149-y","article-title":"The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels","volume":"7","author":"Osusky","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1093\/annonc\/mdq629_bb0110","article-title":"Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma","author":"Hui","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdq629_bb0115","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0120","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1093\/annonc\/mdq629_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq629_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdq629_bb0135","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","article-title":"The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review","volume":"42","author":"Eskens","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdq629_bb0140","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition","volume":"7","author":"Verheul","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdq629_bb0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6604456","article-title":"Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer","volume":"99","author":"van der Veldt","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq629_bb0150","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.21277","article-title":"Hemostatic complications of angiogenesis inhibitors in cancer patients","volume":"83","author":"Elice","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdq629_bb0155","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.clon.2008.02.001","article-title":"Severe epistaxis with tyrosine kinase inhibitors","volume":"20","author":"Hall","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1093\/annonc\/mdq629_bb0160","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2007.08.053","article-title":"High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor","volume":"53","author":"Pouessel","year":"2008","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mdq629_bb0165","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.9584","article-title":"Risk of bleeding in cancer patients treated with the angiogenesis inhibitor bevacizumab: a meta-analysis","volume":"27","author":"Sher","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/COC.0b013e3181a650a6","article-title":"Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma","volume":"33","author":"La Vine","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0175","first-page":"1957","article-title":"Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction","volume":"9","author":"Wachsberger","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq629_bb0180","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1158\/0008-5472.CAN-04-3379","article-title":"Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition","volume":"65","author":"Zips","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq629_bb0185","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdq629_bb0190","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2007.15.8451","article-title":"Bowel perforation after radiotherapy in a patient receiving sorafenib","volume":"26","author":"Peters","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0195","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","article-title":"Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer","volume":"24","author":"Crane","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0200","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0210","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2006.10.2871","article-title":"Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma","volume":"25","author":"Elser","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0215","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq629_bb0220","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10637-009-9296-7","article-title":"Phase II study of sunitinib malate in head and neck squamous cell carcinoma","volume":"28","author":"Choong","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdq629_bb0225","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00280-009-1070-1","article-title":"A phase II study of sunitinib in patients with recurrent and\/or metastatic non-nasopharyngeal head and neck cancer","volume":"65","author":"Fountzilas","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdq629_bb0230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.2009.23.8584","article-title":"Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01","volume":"28","author":"Machiels","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419384911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419384911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/6\/1280\/582083\/mdq629.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:20:30Z","timestamp":1624699230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419384911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0923753419384911"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq629","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}